Forum für Wissenschaft, Industrie und Wirtschaft

Hauptsponsoren:     3M 
Datenbankrecherche:

 

Researchers discover mutations linked to relapse of childhood leukemia

04.02.2013
Finding emerged from 100 billion RNA nucleotides in 10 children with cancer

After an intensive three-year hunt through the genome, medical researchers have pinpointed mutations that leads to drug resistance and relapse in the most common type of childhood cancer—the first time anyone has linked the disease's reemergence to specific genetic anomalies.

The discovery, co-lead by William L. Carroll, MD, director of NYU Langone Medical Center's Cancer Institute, is reported in a study published online February 3, 2013, in Nature Genetics.

"There has been no progress in curing children who relapse, in spite of giving them very high doses of chemotherapy and bone marrow transplants," said Dr. Carroll.

The discovery suggests how scientists may be able to thwart a dangerous form of acute lymphoblastic leukemia, a rapidly progressing blood-borne cancer that strikes about 6,000 people in the United States every year and accounts for more than one in four pediatric cancers. Eventually, such information could help doctors detect the early emergence of chemotherapy-resistant leukemia cells in patients and switch to a different treatment strategy before the disease can fully reassert itself.

In acute lymphoblastic leukemia, abbreviated ALL, the body's bone marrow produces an abnormally large number of lymphocytes, or white blood cells. Improved treatments have increased the overall cure rate to roughly 80 percent. But Dr. Carroll says the prognosis is especially dire for some 20 percent of patients who relapse.

Medical researchers have suspected that the reemergence of disease could be due to drug resistance, but previous efforts had not uncovered any definitive pathway. For the new study, led by Dr. Carroll and graduate student Julia Meyer, researchers at five U.S. institutions spent three years analyzing multiple bone marrow samples from pediatric ALL patients for more clues to the disease's progression.

With the help of the Children's Oncology Group, a multi-institutional clinical trials consortium supported by the National Cancer Institute, the researchers analyzed the entire transcriptome—or the full sequence of RNA —from 10 children with pediatric B lymphoblastic leukemia, the most common subtype of ALL. RNA is an essential intermediary in the cellular process that uses DNA blueprints to assemble specific proteins, thus a leukemia transcriptome gives researchers a view of all active genes within the cancerous cells.

For each patient, the team pieced together a complete sequence of RNA extracted from the bone marrow at three time points: at diagnosis, during remission, and upon relapse some months or years later. All told, the project required the researchers to sequence, or spell out, 100 billion letters of RNA. By comparing the before and after sequences, the team found that each patient had acquired between one and six mutations that changed the genetic code over the course of the disease. In some cases researchers were able to detect these mutations in a very small subset (0.01 percent) of the tissue samples at diagnosis so that these cells likely expanded because their drug resistant properties provided the leukemia cells with a survival advantage.

In all, the team documented 20 relapse-specific mutations—none of which had previously been implicated in ALL recurrences. Intriguingly, two patients harbored a mutation in the same gene, NT5C2, which encodes a protein that normally regulates some building blocks used to construct DNA but also can degrade an important class of drugs called purine analogues used in ALL therapy.

When the researchers fully sequenced the NT5C2 gene in 61 other cases in which pediatric ALL patients had relapsed, they found five more mutations that altered the gene's coding region. Further experiments suggested that these NT5C2 mutations all increased the protein's enzymatic activity, making the cancer cells more resistant to a chemotherapy treatment designed to force the cells to kill themselves. All seven patients with NT5C2 mutations relapsed within three years of the initial diagnosis—an early, particularly hard-to-treat re-emergence likely mediated by the drug resistance.

Armed with the new knowledge, Dr. Carroll says doctors may be better equipped to identify patients likely to relapse. "We plan to test the feasibility of screening patients during therapy using sophisticated sequencing technology to pick up low-level mutations in NT5C2 and other genes indicating that a mutant clone is growing," he says. His team is researching whether that advance warning could allow doctors to administer separate drugs to beat back the cancer cells, and is also working on a strategy to directly inhibit the mutant enzyme.

The study co-authors include Julia A. Meyer, Jinhua Wang, Laura A. Hogan, Smita Dandekar, Zuojian Tang, Jiri Zavadil, Timothy Cardozo, Elizabeth Raetz, and Debra J. Morrison at NYU Langone Medical Center; Jun J. Yang and William E. Evans at St. Jude Children's Research Hospital; Jay P. Patel and Ross L. Levine at Memorial Sloan-Kettering Cancer Center; Paul Zumbo, Sheng Li, and Christopher E. Mason at Weill Cornell Medical College of Cornell University; and Stephen. P. Hunger at the University of Colorado School of Medicine and Children's Hospital Colorado.

The research was supported by the National Institutes of Health and National Cancer Institute, with additional support from the American Society of Hematology and St. Baldrick's Foundation.

About the NYU Cancer Institute:

The research mission of the NYU Cancer Institute is to discover the origins of cancer and use that knowledge to eradicate the personal and societal burden of cancer in our community and around the world. Fifteen research programs are organized as scientific research programs, focused on the fundamental biology of cancer in general, and as disease-specific research programs centered on individual types of cancer, such as breast or lung cancer. Translational research, a hallmark of the institute, is finding new ways to integrate the extraordinary growth and understanding made in basic research with the ever-growing need for the development of new therapies and approaches in the clinic to a variety of cancers that have remained difficult to treat. To help translate discovery into clinical practice, the NYU Cancer Institute has embarked on five programs that integrate efforts in laboratory investigation and clinical care: cancer targets and novel therapeutics, community and environment, integrative health, molecular oncology/cancer genomics, and immune- and stem-cell-based therapies.

About NYU Langone Medical Center:

NYU Langone Medical Center, a world-class, patient-centered, integrated, academic medical center, is one of the nation's premier centers for excellence in clinical care, biomedical research and medical education. Located in the heart of Manhattan, NYU Langone is composed of four hospitals – Tisch Hospital, its flagship acute care facility; the Hospital for Joint Diseases, one of only five hospitals in the nation dedicated to orthopaedics and rheumatology; Hassenfeld Pediatric Center, a comprehensive pediatric hospital supporting a full array of children's health services; and the Rusk Institute of Rehabilitation Medicine, the world's first university-affiliated facility devoted entirely to rehabilitation medicine– plus NYU School of Medicine, which since 1841 has trained thousands of physicians and scientists who have helped to shape the course of medical history. The medical center's tri-fold mission to serve, teach and discover is achieved 365 days a year through the seamless integration of a culture devoted to excellence in patient care, education and research. For more information, go to www.NYULMC.org.

Christopher Rucas | EurekAlert!
Further information:
http://www.nyumc.org

More articles from Life Sciences:

nachricht Gene switch may repair DNA and prevent cancer
12.02.2016 | Institute for Integrated Cell-Material Sciences at Kyoto University

nachricht New method opens crystal clear views of biomolecules
11.02.2016 | Deutsches Elektronen-Synchrotron DESY

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Gravitationswellen 100 Jahre nach Einsteins Vorhersage entdeckt

LIGO öffnet mit der Beobachtung kollidierender schwarzer Löcher ein neues Fenster zum Universum / Entscheidende Beiträge von Forschern der Max-Planck-Gesellschaft und der Leibniz Universität Hannover

Zum ersten Mal haben Wissenschaftler Kräuselungen der Raumzeit, sogenannte Gravitationswellen, beobachtet, die – ausgelöst von einem Großereignis im fernen...

Im Focus: Messkampagne POLSTRACC: Starker Ozonabbau über der Arktis möglich

Die arktische Stratosphäre war in diesem Winter bisher außergewöhnlich kalt, damit sind alle Voraussetzungen für das Auftreten eines starken Ozonabbaus in den nächsten Wochen gegeben. Diesen Schluss legen erste Ergebnisse der vom Karlsruher Institut für Technologie (KIT) koordinierten Messkampagne POLSTRACC nahe, die seit Ende 2015 in der Arktis läuft. Eine wesentliche Rolle spielen dabei vertikal ausgedehnte polare Stratosphärenwolken, die zuletzt weite Bereiche der Arktis bedeckten: An ihrer Oberfläche finden chemische Reaktionen statt, welche den Ozonabbau beschleunigen. Diese Wolken haben die Klimaforscher nun ungewöhnlicherweise bis in den untersten Bereich der Stratosphäre beobachtet.

„Weite Bereiche der Arktis waren über einen Zeitraum von mehreren Wochen von polaren Stratosphärenwolken zwischen etwa 14 und 26 Kilometern Höhe bedeckt –...

Im Focus: AIDS-Impfstoffproduktion in Algen

Pflanzen und Mikroorganismen werden vielfältig zur Medikamentenproduktion genutzt. Die Produktion solcher Biopharmazeutika in Pflanzen nennt man auch „Molecular Pharming“. Sie ist ein stetig wachsendes Feld der Pflanzenbiotechnologie. Hauptorganismen sind vor allem Hefe und Nutzpflanzen, wie Mais und Kartoffel – Pflanzen mit einem hohen Pflege- und Platzbedarf. Forscher um Prof. Ralph Bock am Max-Planck-Institut für Molekulare Pflanzenphysiologie in Potsdam wollen mit Hilfe von Algen ein ressourcenschonenderes System für die Herstellung von Medikamenten und Impfstoffen verfügbar machen. Die Praxistauglichkeit untersuchten sie an einem potentiellen AIDS-Impfstoff.

Die Produktion von Arzneimitteln in Pflanzen und Mikroorganismen ist nicht neu. Bereits 1982 gelang es, durch den Einsatz gentechnischer Methoden, Bakterien so...

Im Focus: Einzeller mit Durchblick: Wie Bakterien „sehen“

Ein 300 Jahre altes Rätsel der Biologie ist geknackt. Wie eine internationale Forschergruppe aus Deutschland, Großbritannien und Portugal herausgefunden hat, nutzen Cyanobakterien – weltweit vorkommende mikroskopisch kleine Einzeller – das Funktionsprinzip des Linsenauges, um Licht wahrzunehmen und sich darauf zuzubewegen. Der Schlüssel zu des Rätsels Lösung war eine Idee aus Karlsruhe: Jan Gerrit Korvink, Professor am KIT und Leiter des Instituts für Mikrostrukturtechnik (IMT) am KIT, nutzte Siliziumplatten und UV-Licht, um den Brechungsindex der Einzeller zu messen.

 

Im Focus: Production of an AIDS vaccine in algae

Today, plants and microorganisms are heavily used for the production of medicinal products. The production of biopharmaceuticals in plants, also referred to as “Molecular Pharming”, represents a continuously growing field of plant biotechnology. Preferred host organisms include yeast and crop plants, such as maize and potato – plants with high demands. With the help of a special algal strain, the research team of Prof. Ralph Bock at the Max Planck Institute of Molecular Plant Physiology in Potsdam strives to develop a more efficient and resource-saving system for the production of medicines and vaccines. They tested its practicality by synthesizing a component of a potential AIDS vaccine.

The use of plants and microorganisms to produce pharmaceuticals is nothing new. In 1982, bacteria were genetically modified to produce human insulin, a drug...

Alle Focus-News des Innovations-reports >>>

Anzeige

Anzeige

IHR
JOB & KARRIERE
SERVICE
im innovations-report
in Kooperation mit academics
Veranstaltungen

SUMA-Kongress 2016 – Die offene Web-Gesellschaft 4.0

12.02.2016 | Veranstaltungen

Career Center deutscher Hochschulen tagen an der Europa-Universität Viadrina

12.02.2016 | Veranstaltungen

Frauen in der digitalen Arbeitswelt: Gestaltung für die IT-Branche und das Ingenieurswesen

11.02.2016 | Veranstaltungen

 
B2B-VideoLinks
Weitere VideoLinks >>>
Aktuelle Beiträge

Ultraschnelle Kontrolle von Spinströmen durch Laserlicht

12.02.2016 | Physik Astronomie

SCHOTT stellt auf der Photonics West zukunftsweisende Lösungen für die Optik vor

12.02.2016 | Messenachrichten

Große Sauerstoffquellen im Erdinneren

12.02.2016 | Geowissenschaften